Healthcare

Corporate Finance & Advisory, International Trade & Development, and Investor Relations

Est. 1989

Introduction

GC Partners has been active in the healthcare, biotech and healthtech since its establishment in 1989
GC Partners has developed relationships throughout Australia, Asia, Europe and the U.S. with public and private hospitals and health check clinics, specialist clinics, pharma, biotech, medical technology, academic institutions, regional associations & societies, medical device, and equipment companies
Developments in technology are moving rapidly and over the next 50 years healthcare investment and expenditures will increase substantially
The Australian Government is investing in a stronger health system as part of its plan for a stronger future through a record AUD132 billion in 2022–23, increasing to AUD140 billion in 2025–26, with a total commitment of AUD537 billion over the next four years.

Australia’s fast-growing life sciences sector is one of the largest in the southern hemisphere. It’s worth more than AUD250 billion and home to more than 2,600+ organisations
Australia’s high-quality and innovative healthcare system is envied around the world. It’s underpinned by a world-class medical research sector, nurtured in our universities and hospitals, medical research institutes and life science companies.

The global biotechnology sector provides social and economic opportunities and benefits. The market is forecast to grow to USD1040 billion by 2030, registering a compound annual growth rate of 7.5% to 2030
Australia has a strong base in biotechnology, with many incentives for R&D and commercialisation. Health and medical research is one of Australia’s strongest research sectors
Australia has unique strengths in undertaking clinical trials to test the efficacy and safety of medical products. Australia’s health system is also one of the most efficient and equitable in the world, ranking in the top 10 globally
The Australian Government will continue to support all parts of the research and development pipeline. It provides incentives to grow Australian sovereign capacity and capability to research and manufacture locally while embedding into a growing international supply-chain for advanced medical products
The global In Vitro Diagnostics market is expected to reach USD130 billion at a CAGR of 4.6% from 2023 to 2030
Australia companies have been slow to take advantage of Asia and Europe in the collaboration and commercialisation of research.

There are clear opportunities in the Asian region for Australian pharma and life science companies looking to secure investors for funding and collaboration partners for research and commercialisation
Companies are seeking an integrated way of working together which involves sharing of skills, resources, infrastructure, and exclusive knowledge, whilst overall care delivery remains fragmented and diverse
Home to more than 60% of the global population, the Asia-Pacific (APAC) region presents an immense commercial opportunity for biopharma, medical device, and healthcare companies. For these life sciences enterprises, APAC also offers highly attractive market entry prospects. Regional healthcare expenditure in APAC is projected to grow and outpace growth in the U.S. and Europe
By 2050, more than a quarter – or 1.3 billion – of the population in Asia Pacific will be considered elderly, or 60 years or older
APAC countries with advanced reimbursement systems or improving healthcare infrastructure have also emerged as lucrative markets. These include countries such as mainland China, Japan, Taiwan, Korea, Australia, Singapore, Indonesia, and Thailand
In 2021, China’s total healthcare expenditure reached RMB 7.6 trillion (approx. USD1.2 trillion), more than doubling from 2015.

Biotechnology companies are increasingly taking on the task of commercialisation. The European market holds USD246 billion potential and many biotech companies are now building a footprint there
Europe remains an important market for launching new drugs, as it accounts for over 20 per cent of the total global pharma market
It comprises thirty one markets across Europe, including the UK and Switzerland
Oncology is the leading therapeutic area for emerging biotech products
Europe boasts its own set of hot spots for biotech and biopharma development
The growth of the European health care market and the growing acceptance of tech solutions in health care fuel the demand for healthtech solutions. An existing skills shortages mean there is extra room for outsourcing solutions and products.